Daily Archives: December 12, 2022
Atezolizumab is approved by FDA for alveolar soft part sarcoma
December 12th, 2022 SarcomaDec 2022: Atezolizumab (Tecentriq, Genentech, Inc.) has been approved by the Food and Drug Administration (FDA) for adult and paediatric patients with unresectable or metastatic alveolar soft part sarcoma who are 2 years of age or older (AS.... Read More
Olutasidenib is approved by FDA for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation
December 12th, 2022 LeukemiaDec 2022: Olutasidenib (Rezlidhia) capsules were approved by the Food and Drug Administration (FDA) for adult patients with relapsed or resistant acute myeloid leukaemia (AML) who have a susceptible IDH1 mutation as identified by an FDA-app.... Read More
New dosing regimen for asparaginase erwinia chrysanthemi (recombinant) is approved by FDA
December 12th, 2022 LeukemiaDec 2022: A new Monday-Wednesday-Friday dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn has been approved by the Food and Drug Administration (Rylaze, Jazz Pharmaceuticals). Patients should receive 25 mg/m2 intramuscular.... Read More